Summary by Futu AI
Recursion Pharmaceuticals, Inc. Director Blake Borgeson is set to sell 20,054 Class A shares on 03/19/2024, as per the latest filing. These shares, initially acquired on 09/01/2016 as founders shares, were part of Borgeson's compensation from the issuer. The sale is expected to yield an aggregate market value of approximately $216,423. Borgeson's transaction history over the past three months includes the sale of 111,717 shares, generating total gross proceeds of around $1,293,849. The upcoming sale follows a series of transactions by Borgeson, with the most recent sale occurring on 03/05/2024.